-

LivaNova to Present at the Berenberg European Conference 2020

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, will participate in discussions at the Berenberg European Conference 2020.

The discussion is scheduled to begin at 4 p.m. Greenwich Mean Time on Wednesday, December 2. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. A replay of the webcast will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event.

About LivaNova

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by any risk factors contained in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova PLC Investor Relations and Media Contacts

Melissa Farina, +1 (281) 228-7262
VP, Investor Relations
InvestorRelations@livanova.com

Deanna Wilke, +1 (281) 727-2764
VP, Corporate Communications
Corporate.Communications@livanova.com

LivaNova PLC

NASDAQ:LIVN
Details
Headquarters: London, United Kingdom
CEO: Vladimir Makatsaria
Employees: 3000
Organization: PUB
Revenues: $1.25B (2024)
Net Income: $63.2M (2024)

Release Summary
LivaNova PLC announced CEO Damien McDonald will participate in discussions at the Berenberg European Conference 2020 on December 2.
Release Versions
$Cashtags

Contacts

LivaNova PLC Investor Relations and Media Contacts

Melissa Farina, +1 (281) 228-7262
VP, Investor Relations
InvestorRelations@livanova.com

Deanna Wilke, +1 (281) 727-2764
VP, Corporate Communications
Corporate.Communications@livanova.com

More News From LivaNova PLC

LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98 F...

Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set for the Company’s OSPREY randomized controlled trial (RCT). The researchers evaluated the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality, when delivered by LivaNova’s aura6000™ System for the treatment of mod...

LivaNova to Announce First-Quarter 2026 Results

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen...
Back to Newsroom